adenovirus serotype 26-expressing HPV16 vaccine JNJ-63682918

A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.